Skip to main content

Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety

Journal of Cancer Research and Clinical Oncology volume 144, pages 157–163 (2018)Cite this article

Abstract

Purpose

To preliminarily evaluate the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) for unresectable soft tissue sarcoma refractory to systemic chemotherapy.

Methods

Ten patients with refractory sarcoma who underwent DEB-TACE therapy between January 2015 and January 2017 were identified. Clinical information and radiological data were retrospectively collected to analyze tumor response, overall survival (OS), progression-free survival and adverse events (AEs). Tumor response to DEB-TACE was assessed with modified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging.

Results

All DEB-TACE procedures were successfully performed for ten patients with 15 tumor lesions. The median follow-up duration was 19 months and the median survival time was 21 months (range 11–30 months). The 1- and 2-year OS rate was 90 and 30%, respectively. According to the guidance of mRECIST, complete response, partial response, stable disease and progressive disease were noted in zero (0%), three (30%), four (40%) and three (30%) patients, respectively. The disease control rate and objective response rate was 70 and 30%, respectively. There were no serious AEs in patients after DEB-TACE.

Conclusions

Our data showed that DEB-TACE was effective and safe for patients with soft tissue sarcoma. Therefore, DEB-TACE can be considered as an alternative treatment option for unresectable soft tissue sarcoma refractory to conventionally systemic chemotherapy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  • Chawla SP, Papai Z, Mukhametshina G et al (2015) First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial. JAMA Oncol 1:1272–1280

    Article  PubMed  Google Scholar 

  • Chegai F, Orlacchio A, Merolla S et al (2015) Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol 2:399–408

    Article  PubMed  PubMed Central  Google Scholar 

  • Constantinidou A, van der Graaf WTA (2017) The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. Eur J Cancer 84:257–261

    CAS  Article  PubMed  Google Scholar 

  • Currie BM, Soulen MC (2017) Decision making: intra-arterial therapies for cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 34:92–100

    Article  PubMed  Google Scholar 

  • Facciorusso A, Mariani L, Sposito C et al (2016) Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 31:645–653

    CAS  Article  PubMed  Google Scholar 

  • Frezza AM, Stacchiotti S, Gronchi A (2017a) Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. BMC Med 15:160

    Article  PubMed  PubMed Central  Google Scholar 

  • Frezza AM, Stacchiotti S, Gronchi A (2017b) Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med 15:109

    Article  PubMed  PubMed Central  Google Scholar 

  • Gbolahan OB, Schacht MA, Beckley EW et al (2017) Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol 8:215–228

    Article  PubMed  PubMed Central  Google Scholar 

  • Gentil K, Lentz CS, Rai R et al (2014) Eotaxin-1 is involved in parasite clearance during chronic filarial infection. Parasite Immunol 36:60–77

    CAS  Article  PubMed  Google Scholar 

  • Gonzalez MV, Tang Y, Phillips GJ et al (2008) Doxorubicin eluting beads-2: methods for evaluating drug elution and in vitro: in vivo correlation. J Mater Sci Mater Med 19:767–775

    CAS  Article  PubMed  Google Scholar 

  • Gorodetski B, Chapiro J, Schernthaner R et al (2017) Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 27:526–535

    Article  PubMed  Google Scholar 

  • Grimer R, Judson I, Peake D et al (2010) Guidelines for the management of soft tissue sarcomas. Sarcoma 2010:506182

    PubMed  PubMed Central  Google Scholar 

  • Gupta S, Gouw L, Wright J et al (2016) Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Invest New Drugs 34:243–252

    CAS  Article  PubMed  Google Scholar 

  • Hong K, Kobeiter H, Georgiades CS et al (2005) Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. J Vasc Interv Radiol 16:1711–1717

    Article  PubMed  Google Scholar 

  • Hong K, Khwaja A, Liapi E et al (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–2567

    CAS  Article  PubMed  Google Scholar 

  • In GK, Hu JS, Tseng WW et al (2017) Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol 9:533–550

    Article  PubMed  PubMed Central  Google Scholar 

  • Jiang C, Wang J, Wang Y et al (2016) Treatment outcome following transarterial chemoembolization in advanced bone and soft tissue sarcomas. Cardiovasc Intervent Radiol 39:1420–1428

    Article  PubMed  Google Scholar 

  • Judson I, Verweij J, Gelderblom H et al (2017) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15:415–423

    Article  Google Scholar 

  • Lee AT, Pollack SM, Huang P et al (2017) Phase III soft tissue sarcoma trials: success or failure? Curr Treat Options Oncol 18:19

    Article  PubMed  PubMed Central  Google Scholar 

  • Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60

    CAS  Article  PubMed  Google Scholar 

  • Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342

    Article  PubMed  Google Scholar 

  • Pasquali S, Gronchi A (2017) Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol 9:415–429

    Article  PubMed  PubMed Central  Google Scholar 

  • Ryan CW, Merimsky O, Agulnik M et al (2016) PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol 34:3898–3905

    Article  PubMed  Google Scholar 

  • Sacco R, Tapete G, Simonetti N et al (2017) Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. J Hepatocell Carcinoma 4:105–110

    Article  PubMed  PubMed Central  Google Scholar 

  • Tang J, Xiao L, Cui R et al (2016) CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells. Oncol Rep 35:1153–1162

    CAS  Article  PubMed  Google Scholar 

  • Tap WD, Jones RL, Van Tine BA et al (2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388:488–497

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  • Tap WD, Papai Z, Van Tine BA et al (2017) Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol 18:1089–1103

    CAS  Article  PubMed  Google Scholar 

  • van der Graaf WTA, Jones RL (2017) Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here? Lancet Oncol 18:706–707

    Article  PubMed  Google Scholar 

  • Zhang S, Huang C, Li Z et al (2017) Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. Drug Deliv 24:1011–1017

    Article  PubMed  Google Scholar 

  • Zou JH, Zhang L, Ren ZG et al (2016) Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 17:510–517

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Grant [2013]163 from the Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology and Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes.

Author information

Affiliations

  1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou, 510120, Guangdong, People’s Republic of China

    Jia-yan Ni, Hong-liang Sun, Yao-ting Chen, Jiang-hong Luo, Wei-dong Wang, Xiong-ying Jiang, Dong Chen & Lin-feng Xu

Authors
  1. Jia-yan Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong-liang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yao-ting Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiang-hong Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei-dong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiong-ying Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lin-feng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lin-feng Xu.

Ethics declarations

Conflict of interest

We declare that we have no conflict of interest.

Funding

This study was funded by the Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology ([2013]163) and the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes (KLB09001).

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ni, Jy., Sun, Hl., Chen, Yt. et al. Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety. J Cancer Res Clin Oncol 144, 157–163 (2018). https://doi.org/10.1007/s00432-017-2530-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-017-2530-3

Keywords

  • Soft tissue sarcoma
  • Drug-eluting bead
  • Transarterial chemoembolization
  • Systemic chemotherapy